|
US20050060764A1
(en)
*
|
2003-09-17 |
2005-03-17 |
Susan Gregory |
Mouse model for bone metabolism
|
|
IL117175A
(en)
*
|
1995-02-20 |
2005-11-20 |
Sankyo Co |
Osteoclastogenesis inhibitory factor protein
|
|
US6919434B1
(en)
|
1995-02-20 |
2005-07-19 |
Sankyo Co., Ltd. |
Monoclonal antibodies that bind OCIF
|
|
US20050147611A1
(en)
*
|
1995-12-22 |
2005-07-07 |
Amgen Inc. |
Combination therapy for conditions leading to bone loss
|
|
US7632922B1
(en)
*
|
1995-12-22 |
2009-12-15 |
Amgen, Inc. |
Osteoprotegerin
|
|
US6479254B2
(en)
|
1996-03-22 |
2002-11-12 |
Human Genome Sciences, Inc. |
Apoptosis inducing molecule II
|
|
US7964190B2
(en)
|
1996-03-22 |
2011-06-21 |
Human Genome Sciences, Inc. |
Methods and compositions for decreasing T-cell activity
|
|
US6495520B2
(en)
|
1996-03-22 |
2002-12-17 |
Human Genome Sciences, Inc. |
Apoptosis Inducing Molecule II and methods of use
|
|
US6635743B1
(en)
|
1996-03-22 |
2003-10-21 |
Human Genome Sciences, Inc. |
Apoptosis inducing molecule II and methods of use
|
|
DK1114864T4
(da)
*
|
1996-12-13 |
2012-09-03 |
Schering Corp |
Pattedyrcelleoverfladeantigener samt tilhørende reagenser
|
|
EP0946725B1
(en)
*
|
1996-12-23 |
2011-01-26 |
Immunex Corporation |
Receptor activator of nf-kappa b, receptor is member of tnf receptor superfamily
|
|
IL130491A
(en)
*
|
1996-12-23 |
2011-10-31 |
Immunex Corp |
Dna encoding rank polypeptide, the rank polypeptide and use thereof
|
|
ATE328006T1
(de)
*
|
1997-04-15 |
2006-06-15 |
Sankyo Co |
Neues protein und verfahren zu dessen herstellung
|
|
AU2008200700C1
(en)
*
|
1997-04-15 |
2013-04-04 |
Daiichi Sankyo Co., Ltd |
Novel Protein and Process for Producing The Same
|
|
US6316408B1
(en)
|
1997-04-16 |
2001-11-13 |
Amgen Inc. |
Methods of use for osetoprotegerin binding protein receptors
|
|
SI0975754T2
(sl)
*
|
1997-04-16 |
2016-04-29 |
Amgen Inc., |
Vezivni proteini in receptorji osteoprotegerina
|
|
CA2229449A1
(en)
*
|
1997-04-25 |
1998-10-25 |
Takeda Chemical Industries, Ltd. |
Novel receptor protein and its use
|
|
WO1998054201A1
(en)
*
|
1997-05-29 |
1998-12-03 |
Human Genome Sciences, Inc. |
Human tumor necrosis factor receptor-like protein 8
|
|
CN1183159C
(zh)
|
1997-09-24 |
2005-01-05 |
三共株式会社 |
破骨细胞形成抑制因子单克隆抗体、其用途和试剂盒
|
|
WO1999029865A2
(en)
*
|
1997-12-12 |
1999-06-17 |
The Rockefeller University |
A protein belonging to the tnf superfamily, nucleic acids encoding same, and methods of use thereof
|
|
US7019119B2
(en)
*
|
1997-12-12 |
2006-03-28 |
The Rockefeller University |
Protein belonging to the TNF superfamily involved in signal transduction, nucleic acids encoding same, and methods of use thereof
|
|
US7063960B2
(en)
*
|
1997-12-12 |
2006-06-20 |
The Rockefeller University |
Protein belonging to the TNF superfamily involved in signal transduction, nucleic acids encoding same, and methods of use thereof
|
|
ATE412746T1
(de)
|
1998-05-14 |
2008-11-15 |
Immunex Corp |
Verfahren zur hemmung der wirkung der osteoklasten
|
|
WO2001060397A1
(en)
|
2000-02-16 |
2001-08-23 |
Genentech, Inc. |
Uses of agonists and antagonists to modulate activity of tnf-related molecules
|
|
US20020106728A1
(en)
*
|
2000-06-20 |
2002-08-08 |
Genentech, Inc. |
NS4 nucleic acids and polypeptides and methods of use for the treatment of body weight disorders
|
|
EP1541587A3
(en)
*
|
1998-09-15 |
2007-06-20 |
Pharmexa A/S |
Method for down-regulating osteoprotegerin ligand activity
|
|
PL196790B1
(pl)
|
1998-09-15 |
2008-01-31 |
Pharmexa As |
Zastosowanie zwierzęcego polipeptydu OPGL lub jego podsekwencji, lub analogu OPGL, zastosowanie fragmentu kwasu nukleinowego, zastosowanie wektora przenoszącego fragment kwasu nukleinowego, zastosowanie niepatogennej transformowanej komórki, zastosowanie kompozycji zawierającej taki fragment lub wektor, sposób identyfikacji zmodyfikowanego polipeptydu OPGL, sposób wytwarzania kompozycji immunogennej
|
|
US6534061B1
(en)
|
1999-04-12 |
2003-03-18 |
Genentech, Inc. |
Tumor necrosis factor receptor homologs and nucleic acids encoding the same
|
|
US6492124B1
(en)
|
1999-06-11 |
2002-12-10 |
The Rockefeller University |
Trance activated signal transduction pathways in osteoclasts
|
|
US6872806B1
(en)
*
|
1999-06-25 |
2005-03-29 |
The Governors Of The University Of Alberta |
Polypeptide compositions formed using a coiled-coil template and methods of use
|
|
ES2392392T3
(es)
|
1999-06-28 |
2012-12-10 |
Genentech, Inc. |
Métodos para producir ligando Apo-2 utilizando iones metálicos divalentes
|
|
US6673771B1
(en)
|
1999-07-28 |
2004-01-06 |
The Trustees Of The University Of Pennsylvania |
Methods of inhibiting osteoclast activity
|
|
CA2647796A1
(en)
*
|
1999-07-28 |
2001-02-08 |
The Trustees Of The University Of Pennsylvania |
Method of inhibiting osteoclast activity
|
|
AUPQ314799A0
(en)
*
|
1999-09-29 |
1999-10-21 |
University Of Western Australia, The |
Bone cell factor
|
|
US6171860B1
(en)
*
|
1999-11-05 |
2001-01-09 |
Isis Pharmaceuticals, Inc. |
Antisense inhibition of rank expression
|
|
WO2001036637A1
(en)
*
|
1999-11-17 |
2001-05-25 |
Immunex Corporation |
Receptor activator of nf-kappa b
|
|
GB9930616D0
(en)
*
|
1999-12-24 |
2000-02-16 |
Mathilda & Terence Kennedy Ins |
Activation and inhibition of the immune system
|
|
DE60134459D1
(de)
†
|
2000-02-23 |
2008-07-31 |
Amgen Inc |
Antagonistische selektive bindungsagenzien des osteoprotegerin-bindungsproteins
|
|
US20030103978A1
(en)
*
|
2000-02-23 |
2003-06-05 |
Amgen Inc. |
Selective binding agents of osteoprotegerin binding protein
|
|
PT2857516T
(pt)
|
2000-04-11 |
2017-08-28 |
Genentech Inc |
Anticorpos multivalentes e utilizações dos mesmos
|
|
HK1054316A1
(zh)
*
|
2000-05-26 |
2003-11-28 |
Smithkline Beecham Corporation |
用於治疗rank配体介导疾病的抗-rank配体单克隆抗体
|
|
ES2317924T3
(es)
|
2000-07-27 |
2009-05-01 |
Genentech, Inc. |
Administracion secuencial de cpt-11 y polipeptido apo-2l.
|
|
US20040247596A1
(en)
*
|
2000-08-18 |
2004-12-09 |
Odgren Paul R. |
TRANCE regulation of chondrocyte differentiation
|
|
EP1458411A2
(en)
*
|
2000-08-21 |
2004-09-22 |
Smithkline Beecham Corporation |
Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders
|
|
WO2002024896A2
(en)
*
|
2000-09-22 |
2002-03-28 |
Immunex Corporation |
Screening assays for agonists or antagonists of receptor activat or of nf-kb
|
|
US7128911B2
(en)
*
|
2001-01-19 |
2006-10-31 |
Cytos Biotechnology Ag |
Antigen arrays for treatment of bone disease
|
|
WO2002064782A2
(en)
*
|
2001-02-09 |
2002-08-22 |
Maxygen Holdings Ltd. |
Rank ligand-binding polypeptides
|
|
US20040132971A1
(en)
*
|
2001-02-09 |
2004-07-08 |
Haaning Jesper Mortensen |
Rank ligand-binding polypeptides
|
|
WO2002080955A1
(en)
*
|
2001-03-22 |
2002-10-17 |
Barnes-Jewish Hospital |
Stimulation of osteogenesis using rank ligand fusion proteins
|
|
US20030013651A1
(en)
*
|
2001-03-22 |
2003-01-16 |
Barnes-Jewish Hospital |
Stimulation of osteogenesis using rank ligand fusion proteins
|
|
MXPA03008595A
(es)
*
|
2001-03-23 |
2003-12-08 |
Genentech Inc |
Usos del ligando opg para modular respuestas inmunes.
|
|
US20040167072A1
(en)
*
|
2001-05-11 |
2004-08-26 |
Aggarwal Bharat B. |
Inhibitors of receptor activator of NF-kappaB and uses thereof
|
|
WO2002092623A1
(en)
*
|
2001-05-11 |
2002-11-21 |
Research Development Foundation |
INHIBITORS OF RECEPTOR ACTIVATOR OF NF-κB AND USES THEREOF
|
|
DE02726901T1
(de)
*
|
2001-05-17 |
2004-07-15 |
Immunex Corp., Seattle |
Therapeutische verwendung von rang-antagonisten
|
|
US20040213788A1
(en)
*
|
2001-05-18 |
2004-10-28 |
Sweet Raymond W. |
Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders
|
|
US20030021785A1
(en)
*
|
2001-06-06 |
2003-01-30 |
Dougall William C. |
Use of rank antagonists to treat cancer
|
|
PL222211B1
(pl)
|
2001-06-26 |
2016-07-29 |
Amgen Fremont Inc |
Przeciwciało przeciwko OPGL, kompozycja je zawierająca, jego zastosowanie i sposób jego wytwarzania, sposób wykrywania poziomu OPGL, kompozycja obejmująca polinukleotydy i komórka gosodarza
|
|
AU2002316384A1
(en)
*
|
2001-06-26 |
2003-03-03 |
Photomed Technologies, Inc. |
Multiple wavelength illuminator
|
|
US7252994B2
(en)
|
2001-07-03 |
2007-08-07 |
Genentech, Inc. |
Human DR4 antibodies and uses thereof
|
|
US20030050223A1
(en)
*
|
2001-08-09 |
2003-03-13 |
Jonathan Lam |
Crystal forms and mutants of RANK ligand
|
|
US20040186051A1
(en)
|
2001-10-02 |
2004-09-23 |
Kelley Robert F |
Apo-2 ligand variants and uses thereof
|
|
CA2463478A1
(en)
*
|
2001-10-12 |
2003-08-14 |
Barnes-Jewish Hospital |
Methods for screening osteogenic compounds
|
|
US20030109444A1
(en)
*
|
2001-10-12 |
2003-06-12 |
Jonathan Lam |
Bone anti-resorptive compounds
|
|
US20030100068A1
(en)
*
|
2001-10-12 |
2003-05-29 |
Jonathan Lam |
RANKL mimics and uses thereof
|
|
IL161387A0
(en)
*
|
2001-10-15 |
2004-09-27 |
Barnes Jewish Hospital |
Rankl mimics and uses thereof
|
|
JP2005521640A
(ja)
|
2001-11-13 |
2005-07-21 |
ジェネンテック・インコーポレーテッド |
Ａｐｏ−２リガンド／ＴＲＡＩＬ製剤
|
|
US7842668B1
(en)
|
2001-11-13 |
2010-11-30 |
Genentech, Inc. |
Apo-2 ligand/trail formulations
|
|
US7741285B2
(en)
|
2001-11-13 |
2010-06-22 |
Genentech, Inc. |
APO-2 ligand/trail formulations
|
|
US20040170602A1
(en)
*
|
2002-01-04 |
2004-09-02 |
Desjarlais John R. |
Dominant negative proteins and methods thereof
|
|
US7381792B2
(en)
*
|
2002-01-04 |
2008-06-03 |
Xencor, Inc. |
Variants of RANKL protein
|
|
AU2003217174A1
(en)
*
|
2002-01-04 |
2003-07-30 |
Xencor |
Novel variants of rankl protein
|
|
US20030166559A1
(en)
*
|
2002-01-04 |
2003-09-04 |
Desjarlais John R. |
Dominant negative proteins and methods thereof
|
|
WO2003080671A1
(en)
*
|
2002-03-21 |
2003-10-02 |
Komed Co., Ltd. |
Anti-rank monoclonal antibodies and pharmaceutical composition containing the same
|
|
CA2481074A1
(en)
*
|
2002-04-05 |
2003-10-23 |
Amgen Inc. |
Human anti-opgl neutralizing antibodies as selective opgl pathway inhibitors
|
|
EP2500032A1
(en)
|
2002-06-24 |
2012-09-19 |
Genentech, Inc. |
APO-2 ligand/trail variants and uses thereof
|
|
US20040138162A1
(en)
*
|
2002-08-30 |
2004-07-15 |
Roodman G. David |
Method of resisting osteoclast formation
|
|
US9453251B2
(en)
|
2002-10-08 |
2016-09-27 |
Pfenex Inc. |
Expression of mammalian proteins in Pseudomonas fluorescens
|
|
EP1578305A4
(en)
*
|
2002-12-10 |
2008-08-27 |
Schering Plough Ltd |
CANIN RANKL AND METHODS OF PREPARATION AND USE THEREOF
|
|
EP1582589B1
(en)
*
|
2003-01-10 |
2010-03-24 |
Protein Crystal Co., Ltd. |
Protein complex, process for producing the same and use thereof
|
|
TWI353991B
(en)
|
2003-05-06 |
2011-12-11 |
Syntonix Pharmaceuticals Inc |
Immunoglobulin chimeric monomer-dimer hybrids
|
|
US7700574B2
(en)
*
|
2003-09-17 |
2010-04-20 |
Isis Pharmaceuticals, Inc. |
Modulation of RANKL expression
|
|
US7252833B2
(en)
*
|
2003-11-18 |
2007-08-07 |
Skeletal Kinetics, Llc |
Calcium phosphate cements comprising an osteoclastogenic agent
|
|
WO2005063170A2
(en)
*
|
2003-12-29 |
2005-07-14 |
Toudai Tlo, Ltd. |
Methods of identifying immunoregulatory agents, immunoregulatory agents, and uses thereof
|
|
KR20060132006A
(ko)
|
2004-03-23 |
2006-12-20 |
비오겐 아이덱 엠에이 아이엔씨. |
수용체 커플링제 및 이의 치료적 용도
|
|
EP2412816B1
(en)
|
2004-07-26 |
2014-12-03 |
Pfenex Inc. |
Process for improved protein expression by strain engineering
|
|
MX2007001221A
(es)
|
2004-08-04 |
2007-03-23 |
Amgen Inc |
Anticuerpos para proteina dickkopf-1 (dkk-1).
|
|
MX2007001469A
(es)
|
2004-08-06 |
2007-03-26 |
Genentech Inc |
Ensayos y metodos que utilizan biomarcadores.
|
|
ZA200701657B
(en)
|
2004-08-06 |
2008-09-25 |
Genentech Inc |
Assays and methods using biomarkers
|
|
JO3000B1
(ar)
|
2004-10-20 |
2016-09-05 |
Genentech Inc |
مركبات أجسام مضادة .
|
|
RU2007119989A
(ru)
*
|
2004-12-02 |
2009-01-10 |
Домантис Лимитед (Gb) |
Композиции, слитые конструкции и конъюгаты plad домена
|
|
US8029783B2
(en)
|
2005-02-02 |
2011-10-04 |
Genentech, Inc. |
DR5 antibodies and articles of manufacture containing same
|
|
PT1915626E
(pt)
|
2005-08-16 |
2012-02-03 |
Genentech Inc |
Sensibilidade da apoptose a apo2l/trail por ensaio de expressão de galnac-t14 em células/tecidos
|
|
ES2618543T3
(es)
|
2005-11-23 |
2017-06-21 |
Genentech, Inc. |
Métodos y composiciones relacionados con ensayos de linfocitos B
|
|
US7795427B2
(en)
*
|
2006-02-14 |
2010-09-14 |
New York University |
Methods for inhibiting osteoclast differentiation, formation, or function and for increasing bone mass
|
|
EP1854458A1
(en)
*
|
2006-05-08 |
2007-11-14 |
IMBA-Institut für Molekulare Biotechnologie GmbH |
Use of a compound with RANKL activity
|
|
EP2020445B1
(en)
|
2006-05-12 |
2013-01-02 |
Keio University |
Detection of inflammatory disease and composition for prevention or treatment of inflammatory disease
|
|
WO2008044379A1
(fr)
|
2006-10-11 |
2008-04-17 |
Oriental Yeast Co., Ltd. |
Modèle animal de perte osseuse
|
|
US20100105612A1
(en)
|
2006-10-11 |
2010-04-29 |
Oriental Yeast Co., Ltd. |
Agent containing fused protein of soluble rankl with epitope tag
|
|
WO2008044797A1
(fr)
|
2006-10-11 |
2008-04-17 |
Oriental Yeast Co., Ltd. |
Animal modèle d'ostéopénie
|
|
US9580719B2
(en)
|
2007-04-27 |
2017-02-28 |
Pfenex, Inc. |
Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
|
|
CA2685326A1
(en)
|
2007-04-27 |
2008-11-06 |
Dow Global Technologies Inc. |
Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
|
|
CN101772351B
(zh)
|
2007-06-05 |
2013-01-02 |
东方酵母工业株式会社 |
新的骨量增加药
|
|
BRPI0813262A2
(pt)
*
|
2007-06-20 |
2015-04-14 |
Schering Corp |
Biomarcadores de destruição de articulação para terapia de doença inflamatória de articulação anti-il-17a
|
|
CN101802008B
(zh)
|
2007-08-21 |
2015-04-01 |
安美基公司 |
人类c-fms抗原结合蛋白
|
|
KR100911852B1
(ko)
|
2007-11-26 |
2009-08-11 |
고려대학교 산학협력단 |
유세포 분석기를 이용한 신규한 ｒａｎｋ와 ｒａｎｋ리간드의 결합 분석방법
|
|
WO2009105934A1
(zh)
*
|
2008-02-27 |
2009-09-03 |
上海先导药业有限公司 |
抗人rankl单克隆抗体
|
|
AR073072A1
(es)
|
2008-08-19 |
2010-10-13 |
Regeneron Pharma |
Anticuerpos humanos para el ligando del activador del receptor de nf-kb (rankl) humano
|
|
US8657662B2
(en)
|
2008-09-04 |
2014-02-25 |
Patent Investment & Licensing Company |
Gaming device having variable speed of play
|
|
US9435811B2
(en)
|
2008-09-30 |
2016-09-06 |
Oriental Yeast Co., Ltd |
Inducer of chondrocyte proliferation and differentiation
|
|
CN101712964B
(zh)
*
|
2008-10-08 |
2013-05-08 |
上海科新生物技术股份有限公司 |
抑制破骨细胞形成的融合蛋白、其制备方法及药物组合物
|
|
MX2011005481A
(es)
|
2008-11-25 |
2011-08-17 |
Biogen Idec Inc |
Uso de antagonistas de receptor de muerte 6 (drg6) y de p75 para promover la supervivencia de células del sistema nervioso.
|
|
CN101514232B
(zh)
*
|
2009-03-25 |
2013-06-19 |
上海科新生物技术股份有限公司 |
一种RANKL-Fc融合蛋白及其制备方法和用途
|
|
JP5746018B2
(ja)
*
|
2009-04-16 |
2015-07-08 |
国立大学法人 東京大学 |
抗ｔｍｐｒｓｓ１１ｅ抗体を用いた癌の診断と治療
|
|
KR101153393B1
(ko)
*
|
2009-09-21 |
2012-06-07 |
고려대학교 산학협력단 |
점변이 이용한 수용성 재조합 인간 ｒａｎｋ의 효능 향상 및 골 질환 치료용 조성물
|
|
EP3372617B1
(en)
|
2010-04-02 |
2024-07-24 |
Amunix Pharmaceuticals, Inc. |
Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same
|
|
DK2591006T3
(da)
|
2010-07-09 |
2019-07-29 |
Bioverativ Therapeutics Inc |
Processerbare enkeltkædede molekyler og polypeptider fremstillet ved anvendelse deraf
|
|
EP2433644A1
(en)
|
2010-09-22 |
2012-03-28 |
IMBA-Institut für Molekulare Biotechnologie GmbH |
Breast cancer therapeutics
|
|
EP2434285A1
(en)
|
2010-09-22 |
2012-03-28 |
IMBA-Institut für Molekulare Biotechnologie GmbH |
Breast cancer diagnostics
|
|
AU2011311452B2
(en)
|
2010-10-06 |
2016-09-01 |
Fundacio Institut De Recerca Biomedica (Irb Barcelona) |
Method for the diagnosis, prognosis and treatment of breast cancer metastasis
|
|
JPWO2012133914A1
(ja)
|
2011-03-31 |
2014-07-28 |
オリエンタル酵母工業株式会社 |
Ｒａｎｋｌアンタゴニストを含む癌免疫増強剤
|
|
WO2013012733A1
(en)
|
2011-07-15 |
2013-01-24 |
Biogen Idec Ma Inc. |
Heterodimeric fc regions, binding molecules comprising same, and methods relating thereto
|
|
FR2980711A1
(fr)
*
|
2011-10-03 |
2013-04-05 |
Centre Nat Rech Scient |
Modulation du systeme immunitaire et des cellules stromales via rank
|
|
CA2854372A1
(en)
|
2011-11-07 |
2013-05-16 |
Universite Laval |
Use of rank/rankl antagonists for treating neuromuscular disorders, genetic myopathies and/or non genetic myopathies and/or for regulating skeletal and cardiac muscle disuse, diseases and aging
|
|
EP2650682A1
(en)
|
2012-04-09 |
2013-10-16 |
Fundació Privada Institut de Recerca Biomèdica |
Method for the prognosis and treatment of cancer metastasis
|
|
CA2875918A1
(en)
|
2012-06-06 |
2013-12-12 |
Fundacio Institut De Recerca Biomedica (Irb Barcelona) |
Method for the diagnosis, prognosis and treatment of lung cancer metastasis
|
|
HK1213946A1
(zh)
|
2012-10-12 |
2016-07-15 |
Inbiomotion S.L. |
用於使用c-maf对前列腺癌转移进行诊断、预後和治疗的方法
|
|
US10119171B2
(en)
|
2012-10-12 |
2018-11-06 |
Inbiomotion S.L. |
Method for the diagnosis, prognosis and treatment of prostate cancer metastasis
|
|
UY35148A
(es)
|
2012-11-21 |
2014-05-30 |
Amgen Inc |
Immunoglobulinas heterodiméricas
|
|
US9708375B2
(en)
|
2013-03-15 |
2017-07-18 |
Amgen Inc. |
Inhibitory polypeptides specific to WNT inhibitors
|
|
AU2014229505B2
(en)
|
2013-03-15 |
2020-02-27 |
Fundacio Institut De Recerca Biomedica (Irb Barcelona) |
Method for the prognosis and treatment of cancer metastasis
|
|
WO2014184679A2
(en)
|
2013-03-15 |
2014-11-20 |
Inbiomotion S.L. |
Method for the prognosis and treatment of renal cell carcinoma metastasis
|
|
UY35463A
(es)
|
2013-03-15 |
2014-10-31 |
Biogen Idec Inc |
Formulaciones de polipéptido fc-factor ix.
|
|
CN105555291B
(zh)
|
2013-08-07 |
2021-08-24 |
助育公司 |
用于治疗雄性不育症的抗体、化合物及其衍生物
|
|
WO2015030701A1
(en)
*
|
2013-08-24 |
2015-03-05 |
R-Pharm Overseas, Inc. |
Fully human antibodies against human rankl
|
|
TW201605896A
(zh)
|
2013-08-30 |
2016-02-16 |
安美基股份有限公司 |
Gitr抗原結合蛋白
|
|
EP3041863A4
(en)
|
2013-09-05 |
2017-08-16 |
Amgen Inc. |
Fc-containing molecules exhibiting predictable, consistent, and reproducible glycoform profiles
|
|
ES2727904T3
(es)
|
2013-10-09 |
2019-10-21 |
Fundacio Inst De Recerca Biomedica Irb Barcelona |
Método para el pronóstico y tratamiento de cáncer metastatizante del hueso que se origina a partir de cáncer de mama
|
|
WO2015087187A1
(en)
|
2013-12-10 |
2015-06-18 |
Rinat Neuroscience Corp. |
Anti-sclerostin antibodies
|
|
SMT202300072T1
(it)
|
2014-03-28 |
2023-05-12 |
Univ Duke |
Cancro della mammella mediante l'utilizzo di modulatori selettivi del recetiore degli estrogeni
|
|
CA2949237C
(en)
|
2014-05-16 |
2022-08-23 |
Amgen Inc. |
Assay for detecting th1 and th2 cell populations
|
|
CA2967224C
(en)
|
2014-12-11 |
2023-08-22 |
Inbiomotion S.L. |
Binding members for human c-maf
|
|
CN104829725A
(zh)
*
|
2015-01-21 |
2015-08-12 |
武汉友芝友生物制药有限公司 |
一种双特异性抗体cd133×cd3的构建及应用
|
|
MX393599B
(es)
|
2015-04-29 |
2025-03-19 |
Radius Pharmaceuticals Inc |
Rad1901 para usarse en el tratamiento de cancer en sujetos con cancer positivo a receptor de estrogeno alfa resistente a farmaco
|
|
EP3298037B1
(en)
|
2015-05-18 |
2019-09-11 |
Eli Lilly and Company |
Anti-dkk-1-anti-rankl bispecific antibody compounds
|
|
JP6598036B2
(ja)
*
|
2015-05-20 |
2019-10-30 |
国立大学法人大阪大学 |
炎症性サイトカイン分泌抑制活性を有するオリゴペプチド
|
|
WO2017120349A1
(en)
*
|
2016-01-05 |
2017-07-13 |
The Trustees Of Columbia University In The City Of New York |
Compositions and methods for regulating activity of inhibitor of dna binding-2 (id2) protein
|
|
WO2017123642A1
(en)
*
|
2016-01-12 |
2017-07-20 |
The Trustees Of The University Of Pennsylvania |
Methods and uses of osteoclast associated receptor (oscar) for prevention and treatment of osteoarthritis
|
|
EP3411066A1
(en)
|
2016-02-01 |
2018-12-12 |
Eli Lilly and Company |
Parathyroid hormone anti-rankl antibody fusion compounds
|
|
WO2017156058A1
(en)
|
2016-03-08 |
2017-09-14 |
Janssen Biotech, Inc. |
Gitr antibodies, methods, and uses
|
|
WO2017203468A1
(en)
|
2016-05-25 |
2017-11-30 |
Inbiomotion S.L. |
Therapeutic treatment of breast cancer based on c-maf status
|
|
AU2017294772B2
(en)
|
2016-07-14 |
2024-05-02 |
Scholar Rock, Inc. |
TGFB antibodies, methods, and uses
|
|
EA201990557A1
(ru)
|
2016-10-28 |
2019-09-30 |
Эли Лилли Энд Компани |
Анти-rankl антитела и их применение
|
|
CN117417263A
(zh)
|
2017-01-05 |
2024-01-19 |
雷迪厄斯制药公司 |
Rad1901-2hcl的多晶型形式
|
|
CA3056011A1
(en)
|
2017-03-14 |
2018-09-20 |
Amgen Inc. |
Control of total afucosylated glycoforms of antibodies produced in cell culture
|
|
AU2018372762B2
(en)
|
2017-11-22 |
2025-08-21 |
Inbiomotion S.L. |
Therapeutic treatment of breast cancer based on c-maf status
|
|
CN111954719B
(zh)
|
2018-03-26 |
2025-07-18 |
美国安进公司 |
细胞培养物中产生的抗体的总去岩藻糖基化糖型
|
|
CN112423844B
(zh)
|
2018-07-04 |
2024-08-13 |
雷迪厄斯制药公司 |
Rad1901-2hcl的多晶型形式
|
|
US11499928B2
(en)
*
|
2018-08-24 |
2022-11-15 |
University Of Wyoming |
Methods and systems for isochoric measurements using differential scanning calorimetry
|
|
EP3860653A1
(en)
|
2018-10-05 |
2021-08-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and systems for controlling the agonistic properties of antibody variable domains by light
|
|
WO2020106886A1
(en)
|
2018-11-20 |
2020-05-28 |
Cornell University |
Macrocyclic complexes of radionuclides and their use in radiotherapy of cancer
|
|
MA54946A
(fr)
|
2019-02-12 |
2021-12-22 |
Radius Pharmaceuticals Inc |
Procédés et composés
|
|
BR112022005583A2
(pt)
|
2019-09-26 |
2022-09-20 |
Amgen Inc |
Métodos para a produção de composições de anticorpos
|
|
EP4110371A1
(en)
|
2020-01-24 |
2023-01-04 |
Radius Health, Inc. |
Methods of stimulating bone growth with abalopartide and denosumab
|
|
CN111793135A
(zh)
*
|
2020-05-11 |
2020-10-20 |
廊坊天光生物技术有限公司 |
一种用于检测血清中rankl含量的抗体对及其用途
|
|
EP4162257A1
(en)
|
2020-06-04 |
2023-04-12 |
Amgen Inc. |
Assessment of cleaning procedures of a biotherapeutic manufacturing process
|
|
KR20230087539A
(ko)
|
2020-10-15 |
2023-06-16 |
암젠 인크 |
항체 생산 방법에서의 상대적인 비결합 글리칸
|
|
TW202317614A
(zh)
|
2021-06-07 |
2023-05-01 |
美商安進公司 |
使用岩藻糖苷酶控制糖基化蛋白的去岩藻糖基化水平
|
|
WO2023059607A1
(en)
|
2021-10-05 |
2023-04-13 |
Amgen Inc. |
Fc-gamma receptor ii binding and glycan content
|
|
CN118139882A
(zh)
*
|
2022-03-24 |
2024-06-04 |
安济盛生物医药有限公司 |
骨骼肌肉系统疾病的治疗
|
|
WO2023198851A1
(en)
|
2022-04-14 |
2023-10-19 |
Institut National de la Santé et de la Recherche Médicale |
Methods for controlling the tumor cell killing by light
|
|
WO2023215725A1
(en)
|
2022-05-02 |
2023-11-09 |
Fred Hutchinson Cancer Center |
Compositions and methods for cellular immunotherapy
|
|
WO2024220916A1
(en)
|
2023-04-20 |
2024-10-24 |
Amgen Inc. |
Methods of determining relative unpaired glycan content
|
|
WO2025038600A1
(en)
|
2023-08-14 |
2025-02-20 |
Amgen Inc. |
Methods for reducing yellow color
|
|
WO2025101820A1
(en)
|
2023-11-08 |
2025-05-15 |
Fred Hutchinson Cancer Center |
Compositions and methods for cellular immunotherapy
|